Group 1 - The core opinion of the legal opinion letter is that the employee stock ownership plan (ESOP) proposed by Shenzhen Kaili Biomedical Technology Co., Ltd. complies with relevant laws and regulations, including the Company Law and Securities Law [2][11][16] - The company has fulfilled the necessary legal procedures for implementing the ESOP, including soliciting employee opinions and obtaining board and supervisory board approvals [12][13][15] - The ESOP is designed to allow employees, including core management, to voluntarily participate, ensuring compliance with the principle of voluntary participation [5][14] Group 2 - The ESOP will be funded through employees' legal salaries, self-raised funds, and other legally permitted means, without the company providing financial assistance or guarantees [5][6] - The total number of shares allocated under the ESOP will not exceed 500,000 shares, representing 0.12% of the company's total equity, with a total funding amount not exceeding 7.965 million yuan [6][8] - The ESOP has a duration of 60 months and a lock-up period of 48 months, with shares vesting in four equal installments [7][8] Group 3 - The management committee will oversee the ESOP, ensuring the protection of participants' rights and compliance with market trading rules [10][11] - The ESOP will not allow forced participation and will adhere to the principle of self-determination for employees [14][15] - The company is required to continuously disclose information regarding the progress of the ESOP in accordance with regulatory requirements [16]

Core Viewpoint - The company has developed a draft for the 2025 Employee Stock Ownership Plan (ESOP) in compliance with relevant laws and regulations, aiming to enhance employee engagement and long-term development [1][2]. Group 1: Compliance and Eligibility - The company confirms that it does not fall under any prohibitive conditions outlined in the relevant guidelines, thus qualifying to implement the ESOP [1]. - The content of the ESOP aligns with the regulations set forth in the guidelines, and employee opinions were thoroughly solicited prior to its introduction [1]. Group 2: Decision-Making Process - The board of directors ensured that related directors recused themselves from voting on the ESOP, validating the legality and effectiveness of the decision-making process [2]. - The remuneration and assessment committee verified that all proposed participants meet the eligibility criteria as per the guidelines, ensuring voluntary participation without coercion [2]. Group 3: Benefits of the ESOP - The implementation of the ESOP is expected to foster a mechanism for sharing achievements and risks between talented employees and shareholders, enhancing employee ownership mentality and optimizing compensation structures [2]. - The plan aims to attract, retain, and motivate outstanding talent, thereby promoting the company's long-term stability and increasing shareholder value [2].

证券简称：开立医疗 证券代码：300633 深圳开立生物医疗科技股份有限公司 （草案） 声明 本公司及全体董事保证本员工持股计划草案及其摘要不存在虚假记载、误 导性陈述或重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律 责任。 风险提示 否获得公司股东大会批准，存在不确定性； 在不确定性； 完成实施，存在不确定性； 资金较低，则本员工持股计划存在不能成立的风险；若员工认购资金不足，则 本员工持股计划存在低于预计规模的风险； 动，投资者对此应有充分准备。 意投资风险。 特别提示 施员工持股计划试点的指导意见》《深圳证券交易所上市公司自律监管指引第 及《公司章程》的规定制定。 派、强行分配等强制员工参加本员工持股计划的情形。 独立董事）、高级管理人员及核心管理人员。拟参与本员工持股计划的员工总 人数不超过 7 人，其中董事（不含独立董事）、高级管理人员 3 人，其他员工 不超过 4 人，具体参与人数以实际自愿参加的员工及其参与情况为准。 股票。本持股计划经公司股东大会审议通过后，将通过非交易过户等法律法规 允许的方式获得公司回购专用证券账户所持有的公司股份。 持股计划董事会决议日至标的股票过户至本持股计 ...

Group 1 - The core viewpoint of the article is the legal opinion regarding Shenzhen Kaili Biomedical Technology Co., Ltd.'s 2025 Restricted Stock and Stock Option Incentive Plan, which aims to establish a long-term incentive mechanism to attract and retain talent while aligning the interests of shareholders, the company, and employees [2][4][6] - The incentive plan includes a total of 5.8818 million shares, accounting for approximately 1.36% of the company's total share capital at the time of the announcement [7][10] - The plan consists of two parts: the second category of restricted stock incentive plan and the stock option incentive plan, with specific conditions for granting and vesting [6][10] Group 2 - The company is a publicly listed entity with a registered address in Shenzhen, engaged in the development and production of medical devices and related software [4][8] - The company has been in operation since its initial public offering on April 6, 2017, under the stock code "300633" [4] - The legal opinion confirms that the company meets the necessary conditions for implementing the stock incentive plan and does not fall under any prohibitive circumstances as outlined in relevant regulations [5][10] Group 3 - The vesting conditions for the restricted stock include performance targets based on net profit growth rates over the years 2025 to 2028, with specific percentage increases required for each vesting period [19][23] - The granting price for the restricted stock is set at no less than 15.93 yuan per share, determined based on the average trading price prior to the announcement [17][18] - The plan outlines a comprehensive assessment system at the company, departmental, and individual levels to evaluate performance and determine the vesting of shares [24][26]

励计划提交股东会审议时公司股本总额的 20%。 员工、单独或合计持有公司 5%以上股份的股东及公司实际控制人的配偶、父母、子女。 深圳开立生物医疗科技股份有限公司董事会 | 深圳开立生物医疗科技股份有限公司 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 一、本激励计划拟授予的第二类限制性股票分配情况 | | | | | | | | | 获授第二类限 | | | | 占本激励计划 | | 占本激励计划 | | | 序号 | 姓名 | 国籍 | 职务 | 制性股票数量 | 授予限制性股 | | 公告日股本总 | | （万股） | | | | | 票总数的比例 | 额的比例 | | | 中层管理人员和技术业务骨干（共 | | | 96 | 人） | 179.4 | 93.73% | 0.41% | | 合计 | | | 191.4 | 100.00% | | 0.44% | | | 注：1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票均未 | | | | | | | | | 超过公司总股本的 | | | ...

Core Viewpoint - Shenzhen Kaili Biomedical Technology Co., Ltd. is undergoing a review of its compliance with various regulations regarding its stock incentive plan and related disclosures [1][3][6]. Compliance Requirements - The financial report for the most recent accounting year did not receive a negative opinion or inability to express an opinion from the registered accountant [3]. - There have been no instances in the last 36 months where profit distribution was not conducted according to laws, regulations, or company articles [3]. - The stock incentive plan must not exceed 20% of the company's total share capital [3][4]. Incentive Object Compliance - The incentive plan includes individuals holding 5% or more of the company's shares, with justifications for their inclusion [3][4]. - No major violations leading to administrative penalties from the China Securities Regulatory Commission (CSRC) have occurred in the last 12 months [3][4]. - The plan must disclose the names, positions, and number of rights granted to directors and senior management [4][5]. Disclosure Completeness - The plan must detail compliance with the Stock Incentive Management Measures, including the purpose and scope of the incentive [4][5]. - The total number of rights to be granted and their percentage of the company's total share capital must be specified [4][5]. - The plan must include the effective period, authorization date, and conditions for exercising rights [4][5]. Performance Assessment - The performance assessment indicators for exercising rights must be disclosed, ensuring they are objective and reasonable [4][5]. - The plan must clarify the rights and obligations of both the company and the incentive objects, including dispute resolution mechanisms [5][6]. Legal and Procedural Compliance - The company must ensure that the stock incentive plan does not harm the interests of the company and all shareholders [5][6]. - Legal opinions from law firms must be obtained to confirm compliance with relevant regulations [5][6].

证券代码：300633 证券简称：开立医疗 深圳开立生物医疗科技股份有限公司 （草案） 声明 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公司所有激励对象承诺，公司因信息披露文件中有虚假记载、误导性陈述 或者重大遗漏，导致不符合授予权益或权益归属/行权安排的，激励对象应当自 相关信息披露文件被确认存在虚假记载、误导性陈述或者重大遗漏后，将由公司 特别提示 一、《深圳开立生物医疗科技股份有限公司 2025 年限制性股票与股票期权 激励计划（草案）》（以下简称"本激励计划"）系依据《中华人民共和国公司 法》《中华人民共和国证券法》《上市公司股权激励管理办法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》等其他有关法律、法规、规范性文件，以及《深圳开立生物医 疗科技股份有限公司章程》制订。 二、本激励计划采取的激励工具为限制性股票（第二类限制性股票）和股 票期权。股票来源为深圳开立生物医疗科技股份有限公司（以下简称"公司" 或"本公司"）向激励对象定向发行公司 A ...

第二条 持有人确定的法律依据 《自律监管指引第 2 号》等有关法律、法规、规范性文件及《公司章程》的相关 规定确定。持有人按照依法合规、自愿参与、风险自担的原则参加本员工持股 计划，不存在以摊派、强行分配等方式强制员工参与的情形。 深圳开立生物医疗科技股份有限公司 第一章 总则 第一条 为规范深圳开立生物医疗科技股份有限公司（以下简称"公司"） 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、《关于上市公司实施员工持股计 划试点的指导意见》（以下简称"《指导意见》"）、《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》（以下简称"《自律 监管指引第 2 号》"）等相关法律法规、规范性文件和《公司章程》、《深圳 开立生物医疗科技股份有限公司 2025 年员工持股计划（草案）》（以下简称 "本员工持股计划"）的规定，特制定《深圳开立生物医疗科技股份有限公司 法"）。 第二章 员工持股计划持有人的确定依据 公司）董事（不含独立董事）、高级管理人员；（2）公司（含控股子公司）核 心管理人员。所有持有人均在公司（含控股子公司）任职， ...

Core Viewpoint - Shenzhen Kaili Biomedical Technology Co., Ltd. is implementing a stock incentive plan to attract and retain talent, aligning the interests of shareholders, the company, and employees for long-term development [1][2]. Summary by Sections 1. Purpose of Assessment - The assessment aims to establish a long-term incentive mechanism to attract and retain talent, enhancing employee motivation and creativity while aligning the interests of shareholders, the company, and employees [1]. 2. Principles of Assessment - The assessment must adhere to principles of fairness, openness, and impartiality, closely linking the stock incentive plan with the performance and contributions of the incentivized individuals to maximize the interests of the company and all shareholders [2]. 3. Assessment Targets - The assessment applies to all participants in the stock incentive plan, including certain directors, senior management, middle management, and key technical personnel, excluding independent directors, supervisors, foreign employees, and shareholders holding more than 5% of the company's shares [2]. 4. Assessment Organization - The Board of Directors' Compensation and Assessment Committee is responsible for organizing and reviewing the assessment, while a working group composed of the Board Office, Human Resources Department, and Finance Department will implement the assessment [2]. 5. Assessment Indicators and Standards - The performance assessment for the stock incentive plan spans from 2025 to 2028, with specific net profit growth targets set for each year based on the 2024 net profit of 136.49 million yuan, requiring growth rates of at least 30% in 2025, 70% in 2026, 150% in 2027, and 260% in 2028 [3]. 6. Implementation of the Plan - If the company fails to meet the performance targets in any assessment year, the corresponding restricted stocks and stock options for that year will not vest or be exercised, and will be rendered void [3][4]. 7. Assessment Period and Frequency - The assessment period for the stock incentive plan is set for four accounting years from 2025 to 2028, with assessments conducted annually [4]. 8. Assessment Procedure - The assessment working group collects relevant business and financial data, evaluates whether the company and individuals meet the performance targets, and submits a performance assessment report to the Compensation and Assessment Committee [4][5]. 9. Management of Assessment Results - Assessment results will be communicated to the assessed individuals within seven working days, allowing for appeals, which must be reviewed within five working days [5].

本激励计划有效期自第二类限制性股票/股票期权授予/授权之日起至激励对象获授的第二类限制性股票/ 股票期权全部归属/行权或作废失效/注销之日止，最长不超过60个月。 开立医疗（300633）(300633.SZ)披露2025年限制性股票与股票期权激励计划(草案)，公司拟向激励对象 授予第二类限制性股票数量为191.4万股，授予396.78万份股票期权。本激励计划第二类限制性股票的授 予价格为不低于15.93元/股，股票期权的行权价格为不低于31.86元/份。本激励计划授予的激励对象总 人数共计406人，包括公司部分董事及高级管理人员、公司(含分公司及控股子公司)中层管理人员和技 术业务骨干。 ...